MX2013001402A - Proceso para preparar tubulisinas. - Google Patents

Proceso para preparar tubulisinas.

Info

Publication number
MX2013001402A
MX2013001402A MX2013001402A MX2013001402A MX2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A MX 2013001402 A MX2013001402 A MX 2013001402A
Authority
MX
Mexico
Prior art keywords
processes
tubulysins
naturally occurring
preparing
preparing tubulysins
Prior art date
Application number
MX2013001402A
Other languages
English (en)
Inventor
Iontcho Radoslavov Vlahov
Christopher Paul Leamon
Katheryn Marie Stanford
Michael Groaning
Paul Joseph Kleindl
Hari Krishna R Santhapuram
Fei You
Kevin Yu Wang
Le-Cun Xu
Allen Ritter
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of MX2013001402A publication Critical patent/MX2013001402A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las tubulisinas son una serie de agentes citotóxicos de origen natural que son de interés como agentes terapéuticos anticancerosos. Se describen los procesos e intermediarios útiles para preparar las tubulisinas de origen natural y de origen no natural y los análogos y derivados de las mismas.
MX2013001402A 2010-08-06 2011-08-05 Proceso para preparar tubulisinas. MX2013001402A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37143310P 2010-08-06 2010-08-06
PCT/US2011/046797 WO2012019123A1 (en) 2010-08-06 2011-08-05 Processes for preparing tubulysins

Publications (1)

Publication Number Publication Date
MX2013001402A true MX2013001402A (es) 2013-08-29

Family

ID=45559842

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001402A MX2013001402A (es) 2010-08-06 2011-08-05 Proceso para preparar tubulisinas.

Country Status (13)

Country Link
US (3) US8889880B2 (es)
EP (1) EP2600866A4 (es)
JP (1) JP2013535220A (es)
KR (1) KR20130096712A (es)
CN (1) CN103140227B (es)
AU (1) AU2011285532B2 (es)
BR (1) BR112013003004A2 (es)
CA (1) CA2807511A1 (es)
EA (1) EA025471B1 (es)
HK (1) HK1185558A1 (es)
MX (1) MX2013001402A (es)
SG (1) SG187728A1 (es)
WO (1) WO2012019123A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
EP2600866A4 (en) * 2010-08-06 2013-12-11 Endocyte Inc PROCESS FOR THE PRODUCTION OF TUBULYSINES
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) * 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
IN2015DN04147A (es) 2012-10-16 2015-10-16 Endocyte Inc
WO2014078484A1 (en) 2012-11-15 2014-05-22 Endocyte, Inc. Conjugates for treating diseases caused by psma expressing cells
US20140249315A1 (en) * 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
JP2017512765A (ja) 2014-04-11 2017-05-25 メディミューン，エルエルシー 二重特異性ｈｅｒ２抗体
CA2962783A1 (en) 2014-10-01 2016-04-07 Medimmune, Llc Method of conjugating a polypeptide
CA2977589A1 (en) * 2015-02-25 2016-09-01 William Marsh Rice University Desacetoxytubulysin h and analogs thereof
AU2016352967A1 (en) 2015-11-10 2018-06-21 Medimmune, Llc Binding molecules specific for ASCT2 and uses thereof
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
RU2018128784A (ru) 2016-01-27 2020-02-27 МЕДИММЬЮН, ЭлЭлСи Способы получения антител с заданным профилем гликозилирования
SG11201808979UA (en) 2016-04-15 2018-11-29 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
EP3661963A1 (en) 2017-08-01 2020-06-10 MedImmune, LLC Bcma monoclonal antibody-drug conjugate
WO2019108685A1 (en) 2017-11-29 2019-06-06 William March Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
WO2022053650A1 (en) 2020-09-11 2022-03-17 Medimmune Limited Therapeutic b7-h4 binding molecules
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
US20230183358A1 (en) 2021-11-10 2023-06-15 Astrazeneca Ab Antibody molecules and conjugates
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
WO2023169896A1 (en) 2022-03-09 2023-09-14 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US7816377B2 (en) 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
EP1521769B1 (de) 2002-07-09 2015-09-09 Dömling, Alexander Tubulysinkonjugate
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
NZ541846A (en) 2003-01-27 2008-12-24 Endocyte Inc Vitamin receptor binding drug delivery conjugates
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
DE102009032972A1 (de) 2009-07-14 2011-01-20 Erbe Elektromedizin Gmbh Vorrichtung zur Herstellung von Anastomosen
WO2011069116A1 (en) 2009-12-04 2011-06-09 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
WO2011106639A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2600866A4 (en) * 2010-08-06 2013-12-11 Endocyte Inc PROCESS FOR THE PRODUCTION OF TUBULYSINES

Also Published As

Publication number Publication date
SG187728A1 (en) 2013-03-28
US20130137139A1 (en) 2013-05-30
EA025471B1 (ru) 2016-12-30
HK1185558A1 (zh) 2014-02-21
US20150225447A1 (en) 2015-08-13
WO2012019123A1 (en) 2012-02-09
US9499849B2 (en) 2016-11-22
EP2600866A4 (en) 2013-12-11
CN103140227B (zh) 2016-01-20
AU2011285532B2 (en) 2015-09-10
KR20130096712A (ko) 2013-08-30
BR112013003004A2 (pt) 2016-06-14
US9273091B2 (en) 2016-03-01
AU2011285532A1 (en) 2013-02-21
EP2600866A1 (en) 2013-06-12
CA2807511A1 (en) 2012-02-09
EA201390203A1 (ru) 2013-08-30
CN103140227A (zh) 2013-06-05
US8889880B2 (en) 2014-11-18
JP2013535220A (ja) 2013-09-12
US20160177363A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
MX2013001402A (es) Proceso para preparar tubulisinas.
MD20150091A2 (ro) Compuşi antivirali
SG190785A1 (en) Antiviral compounds
MX349004B (es) Nuevos compuestos.
MY168300A (en) Pharmaceutical Composition for Inhalation
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12014501258A1 (en) Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
PH12015500376A1 (en) Novel bicyclic pyridinones
MX2013004061A (es) Analogos de ciclosporina.
MX2014004196A (es) Citramida de rasagilina.
PH12014502032A1 (en) Treatment of brain cancer
PL402710A1 (pl) Kompozycje farmaceutyczne zawierajace imatinib lub jego farmaceutycznie dopuszczalna sól oraz sposoby ich otrzymywania
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MX348393B (es) Polimorfo de rifaximina y proceso para la preparacion del mismo.
MX2013004062A (es) Analogos de ciclosporina.
MX2014013238A (es) Produccion de principios farmaceuticos activos estériles.
EP3641891A4 (en) SYNTHESIS OF DISORAZOLES AND THEIR ANALOGUES AS POWERFUL ANTI-CANCER AGENTS
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
IN2014DN03010A (es)
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
IN2013MU03317A (es)
MX351961B (es) Analogos de diazonamida.
MX2013005624A (es) Nuevos derivados de indolizina, su preparacion y su aplicacion en terapeutica.
TN2013000035A1 (en) Highly crystalline valsartan

Legal Events

Date Code Title Description
FG Grant or registration